3-METHOXY-4-(TRIFLUOROMETHYL)PHENYLACETIC ACID, 95%, 1g

TRANS-TERT-BUTYL 3-(HYDROXYMETHYL)-4-(TRIFLUOROMETHYL)PYRROLIDINE-1-CARBOXYLATE, 95.0%, 250mg

N-Fmoc-L-2-Aminophenylpentanoic acid, 95.0%, 100mg

Methyl4-hydroxy-3,5-dimethyl-benzoate, 98+%, 1g

3-Oxo-3-(piperazin-1-yl)propanenitrile hydrochloride, 97%, 10g

METHYL 2-METHYL-3-(TRIFLUOROMETHYL)BENZOATE, 95.0%, 1g

(4-(Isobutylsulfonyl)phenyl)boronic acid, 95.0%, 5g

E-Plan phase EPLPHi 20x/0.40 infinity corrected IOS objective. Working distance 2.61 mm

4-Ethoxycarbonyl-2-fluorophenylisothiocyanate, 98.0%, 1g

2-Fluoro-[1,1'-biphenyl]-4-carboxylic acid, 95.0%, 250mg

Tri-p-tolylamine, 95.0%, 100g

1,2,3,4-Tetrahydro-isoquinoline-1-carboxylic acidethyl ester hydrochloride, 97.0%, 5g

2-Bromoethyl ethyl ether (stabilised with Potassium Carbonate), 90.0%, 25g